Clinical trials covering the immunogenicity of a vaccine aim to study the longitudinal dynamics of certain immune cells after vaccination. The corresponding immunogenicity datasets are mainly analyzed by the use of statistical (mixed effects) models. This paper proposes the use of mathematical ordinary differential equation (ODE) models, combined with a mixed effects approach. ODE models are capable of translating underlying immunological post vaccination processes into mathematical formulas thereby enabling a testable data analysis. Mixed models include both population-averaged parameters (fixed effects) and individual-specific parameters (random effects) for dealing with inter-and intra-individual variability, respectively. This paper models B-cell and T-cell datasets of a phase I/II, open-label, randomized, parallel-group study in which the immunogenicity of a new Herpes Zoster vaccine (Shingrix) is compared with the original Varicella Zoster Virus vaccine (Varilrix).
Introduction

1
Vaccines are developed in order to activate (and subsequently cause proliferation) of T-cells have a direct cytotoxic function and can target host cells that are infected by a 10 pathogen.
11
The vaccine-induced B-cells and T-cells are hypothesized to be capable of preventing 12 or minimizing the morbidity related to the infectious disease against which the vaccine 13 is targeted. Vaccine immunogenicity trials aim to study the longitudinal dynamics of 14 the specific immune response following vaccination. These trials can range from several 15 months to several decades. The quantitative analysis of longitudinal immune response 16 data has evolved from between-group and time point comparisons to statistical 17 regression analyses [1, 2, 3] . Current state-of-the art statistical analyses of longitudinal 18 data consist of a mixed effects model approach in which a separation is made between 19 population-averaged parameters (so called fixed effects) and individual-specific 20 parameters (so called random effects). More recently, Andraud et al. [4] and Le et al.
21
[5] published the first papers in which the mixed effects modeling approach was 22 combined with the use of ordinary differential equations (ODE), thereby more closely 23 resembling immune response dynamics post vaccination. Whereas [4] focused on the 24 long term dynamics following vaccination, [5] focused on the short term dynamics 25 following vaccination.
26
ODE-based mathematical models are capable of translating the underlying 27 immunological/biological theory into a testable data analysis. Moreover, the 28 combination with mixed effects modeling offers a methodology capable of dealing with 29 inter-and intra-individual variability. As such, the use of ODE-based mixed effects 30 models offers a suitable framework for handling longitudinal vaccine immunogenicity 31 data.
32
In this paper, we set out to use ODE-based mixed effects models to study B-cell and 33 T-cell dynamics following varicella-zoster virus (VZV) vaccinations in VZV-immune adults. In particular, this framework will allow us to disentangle the immunogenic 35 differences between two different VZV-specific vaccines.
36
In the Materials and methods section, we first present the immunogenicity data from 37 two VZV vaccine studies consisting of B-cells and CD4+ T-cells of participants at 38 different time points. We then describe the differential equations, the ODE and the 39 ODE-based mixed effects models used to describe the immune response dynamics 40 within each individual as well as the associated model selection procedures. In the 41 Results section we apply the above methods and select a suitable model for each 42 dataset. Next, we compare the results of the two VZV vaccines, using a group-related 43 effect on a chosen parameter. Correlations in and between the datasets are also 44 explored. Finally, we review our findings in the Discussion section. adults, two groups of young adults (18-30 years) were vaccinated with two vaccine doses 52 two months apart. The first group (GROUP 1; sample size: n 1 = 10) received one dose 53 of HZ/su and one dose of OKA concomitantly at month 0 and month 2 (i.e. four doses 54 in total), whereas the second group (GROUP 2; n 2 = 10) received a dose of HZ/su both 55 times (i.e. two doses in total).
56
After vaccine safety was confirmed, three groups of older adults (50-70 years) were 57 vaccinated two months apart, one group (GROUP 3; n 3 = 45) received twice a single 58 dose of HZ/su, the second (GROUP 4; n 4 = 45) twice a single dose of OKA and the last 59 (GROUP 5; n 5 = 45) twice two concomitant doses of HZ/su and OKA. So, all in all, 155 60 participants were divided over these 5 groups. The properties of each group are 61 summarized in Table 1 .
62
Safety and immunogenicity were assessed for all groups up to 12 months 63 post-vaccination in the original study. In order to obtain long-term immunogenicity 64 data on the newly proposed HZ/su vaccine, 23 individuals from the groups solely 65 receiving HZ/su (i.e. GROUPS 2 and 3) were assessed up to 42 months post-vaccination 66 in the extension studies: BIO109671 and BIO109674. We refer to [6] for a more in 67 depth description of the design and results of these studies. considering the second vaccination at month 2.
83
We observe an increase in B-cells, or antibody-secreting cells (ASC), after vaccination 84 at time t = 0 months. At time t = 2 months, the subjects were re-vaccinated, but no 85 data were collected at that time point. Fig 1 shows only the time points for which data 86 were available ( t = 0, 1 and 12 months). Since it is reasonable to expect a (higher) peak 87 in the data after the second dose at t = 2 months, we will assume a time period
88
[0, h], h > 0 during which the level of B-cells increases up to a point, h, after which it 89 decreases. The data plots of gE-specific ASC show a similar pattern (see Fig S1) .
90
T-cell data
91
Intracellular cytokine staining (ICS) in combination with a flow cytometric readout was 92 performed to measure the amount of CD4+ T-cells that produced at least 2 cytokines
93
(interferon-gamma, interleukin 2, CD40 Ligand, tumor necrosis factor alpha) using both 94 Varilrix and gE as stimuli (in separate experiments). The subsequent two datasets 95 comprise the same 155 participants, but now with time points at baseline, and at 1, 2, 3 96 and 12 months after receiving the first vaccine dose. The total VZV-specific T-cell 
102
Given that T-cell data were collected at more time points than B-cell data, we now 103 observe a second peak in the group-specific data plots, as is expected given the vaccine 104 administrations at month 2. Therefore we will use two time periods [0,
105 (with 0 < h 1 < 2 < h 2 ) during which the level of T-cells first increases and then 106 decreases. In case only one peak is observed, we will assume h 1 = 2 < h 2 .
107
As with the B-cell profiles, the gE specific T-cell profiles are shown in Fig S2. 
108
Mathematical methods
109
We used systems of (nonlinear) ODEs to model the B-cell and T-cell dynamics. We 110 applied a systematic approach to fit and compare several models in order to obtain the 111 models that best describe the available data, while providing sufficient biological in S1 Appendix. In the following subsections we provide the basic rationale of these
114
ODEs for both B-cell and T-cell dynamics, respectively.
115
B-cell dynamics models
116
We describe the dynamics of the antibody secreting B-cells (ASC), using the following 117 ODE:
where 
139
To distinguish between models B3 and B4, the dynamics of LASC are considered. The design of the T-cell models follows a similar procedure as that of the B-cell models. 148 The following ODE describes the basic dynamics of the stimulus-specific T-cell 149 population:
with T 0 = T (0) the number of T-cells at time 0 (months). In this equation, f 1 (T )
151
describes the proliferation of T-cells after the first vaccination event at time 0, which 152 will occur until a certain time point h 1 (with 0 < h 1 ≤ 2). Afterwards, no T-cells will be 153 activated until the second vaccination event 2 months after the first, which f 2 (T ) 
T-cells (long living).
178
The dynamics of the short living T-cells are similarly described as in models T1 and 179 T2: a constant number of short living T-cells will be activated after each vaccination
180
(not necessarily the same number), while the decay of short living T-cells occurs at all 181 times at a constant decay rate. For models T3 and T4, the assumption is made that the 182 total number of long living T-cells remains constant over time. If we add the distinction 183 between models with equal and different functions f 1 and f 2 , we arrive at models T3 184 and T4, respectively. Adding proliferation rates of long living T-cells after each 185 vaccination, models T3 and T4 are extended to yield models T5 and T6. In order to 186 restrict the total number of parameters, the long living T cell proliferation rates are 187 assumed to be equal. Table 3 summarizes the parameters used in the functions of the 188 different models. log-normally distributed with E(u i ) = 1.
197
In case of the presence of a categorical variable (e.g. different group in vaccine trial 198 study), the different groups can be compared against each other by adding a component 199 β j to the distribution of a certain parameter. β j describes how for group j, this and sample sizes resulted in non-convergence. Therefore, simplifying assumptions 218 needed to be made. One such simplifying assumption is presuming that the decay of B 219 or T-cells is identical for all individuals, implying that the random effect for that decay 220 parameter is omitted from the model.
221
For both the B-cell and T-cell data sets, the following procedure was used for 222 comparing and selecting the most suitable biologically plausible model to describe the 223 data. In a first step, a list of models was composed, consisting of models B1 to B4 for 224 the B-cell data and of models T1 to T6 for T-cell data, together with assumptions on 225 the parameters reflecting whether or not individual variation on these parameters is 226 present, i.e. whether or not random effects were included for the different parameters. 227 The model parameters were then estimated with the Monolix software. calculate the maximal information coefficient (MIC). This is a way to detect linear and 263 non-linear relations between variables, and can thereby be used to indicate whether a 264 linear relation is feasible by comparing it with the R-squared value [9] . In addition we 265 compute the Spearman correlation. 
270
Results
271
Model selection of B-cell datasets 272 We started by modeling the Varilrix-specific B-cell dataset, for which the model selection 273 procedure outlined in the Inference and model selection section was followed. The upper 274 part of Table 4 summarizes the differences between all models that were tested. B3c, uASC and h, respectively, were set as fixed population parameter. Model B3b was 288 the only model that showed convergence, with an AIC value of 6541.
275
289
The last model examined was model B4, in which a proliferation rate for LASC was 290 added. Many assumptions on the parameters were made; the decay rate of ASC 291 (uASC), proliferation rate of LASC (aLASC) and activation period (h) were set as fixed 292 parameters in models B4b, B4c and B4d, respectively. Combinations of these fixed 293 parameters were considered as well in models B4f, B4g and B4h. Apart from this, we 294 also looked at different group specific parameters, not only the proliferation rate of 295 SASC (aSASC) was considered, but the proliferation rate of long living B-cells (aLASC) 296 as well. Model B4g was the only model that accounted for aSASC and aLASC and still 297 converged. In this model, both aLASC and uASC were set as fixed population 298 parameters, and aSASC was considered to be a group specific parameter. This model 299 had the lowest AIC value of 6524 among all aforementioned models, and was selected as 300 first candidate model.
301
The bootstrap that subsequently was performed did not converge for model B4g, Table 5 . Parameter estimates and corresponding 95% confidence intervals (CI) of final model B3b. SASC(0) is assumed to be zero, LASC 0 = LASC(0) denotes the initial number of LASC. The proliferation of SASC is constant in time period (0, h), at rate aSASC and assumed to be group-specific with effects β i (i = 1, 2, 3, 5). Decay of SASC happens at rate uSASC. The number of LASC remains constant through time.
317
The same models as with the Varilrix-specific B-cell data were used for the 318 gE-specific B-cell data and a similar model selection procedure was followed. For more 319 details, we refer to S3 Appendix. The outcome of the model selection, was model B1a, a 320 model which does not differentiate between SASC and LASC. In time period (0, h), a 321 constant number of ASC are activated. All parameters are assumed to have random 322 effects and the activation rate of ASC is chosen as group-specific parameter. The 323 parameter estimations, along with confidence interval, are shown in Table 6 . Parameter estimates and corresponding 95% confidence intervals (CI) of final model B1a. No distinction between SASC and LASC is presumed. ASC 0 = ASC(0) denotes the initial number of ASC. The proliferation of ASC is constant in time period (0, h), at rate aASC and assumed to be group-specific with effects β i (i = 1, 2, 3, 5). Decay of ASC happens at rate uSASC.
324
Model selection of T-cell datasets
325
Just like with the B-cell models, the most simplistic T-cell model T1 was considered 326 first, in which a 1 T = a 2 T = aT . Model T1a assumed all parameters had random effects, 327 and the activation of T-cells (aT ) had a group-specific effect. An AIC value of 11,664 328 was obtained.
329
When assuming a 1 T = a 2 T , we arrived at model T2. First, the assumption was 330 made that all parameters had random effects, and both a 1 T and a 2 T had a 331 group-specific effect in model T2a. This model converged, with an AIC value of 11,658. 332 When assuming only a 2 T had a group-specific effect (model T2b), a slightly lower AIC 333 value was obtained at 11,655.
334
Next, a distinction between short and long living T-cells (ST and LT, respectively) 335 was considered. In model T3a, all parameters had random effects and aST 336 (= a 1 ST = a 2 ST ) had a group-related effect resulting in an AIC value of 11,637. Model 337 T3b, in which uT was a fixed parameter, did not reach convergence.
338
Model T4 assumed different activation rates of T-cells after each vaccination. When 339 all parameters had random effects, and both a 1 T and a 2 T were group specific, SAEM 340 convergence was not reached (model T4a). When only a group specific effect on a 2 T 341 was assumed (model T4b), convergence was achieved resulting in an AIC value of 342 11,615. Subsequently, uT was set as fixed parameter in models T4c and T4d, again with 343 group specific effects on both activation rates (T4c) and on a 2 T only (T4d),
344
respectively. Both models showed SAEM convergence with an AIC value of 11,646 and 345 a lower AIC value of 11,626, respectively.
346
When assuming LT activation according to a constant proliferation rate (equal after 347 each vaccination in order to limit the number of parameters to be estimated), models 348 T5 and T6 were reached. In models T5, the activation rates of ST were presumed equal 349 after each vaccination. Together with the assumption that all parameters were random, 350 and aST was a group specific parameter, this leaded to model T5a, where an AIC value 351 of 11,631 was found. We note that setting aLT as a group specific parameter was tested 352 as well, but none of these models (including the following) showed convergence and thus 353 were omitted from T4b  no  T6f  no  T4d  no  T6d  no  T5a  no  T5b  no  T3a  66 %  no  T3a' 67 % no Above: Overview of the different models used to model the Varilrix-specific T-cell data. First column: model identifier. Second column: parameters selected as fixed population parameter. Third column: parameter which is chosen to be group-specific. Fourth column: AIC value of each model, in case of convergence. Under: Overview of the considered candidate models (first column) used in the Varilrix-specific T-cell data model selection procedure. Second column: convergence results of the performed bootstraps. Third column: the results of possible IDs with deviating presence in the converging bootstrap samples. Fourth column: results of a bootstrap performed on the Varilrix-specific T-cell dataset, in case IDs are found.
In Models T5b and T5c, respectively, uT and aLT were assumed to be fixed non-converging bootstrap datasets was performed, but no such profile was identified.
376
Taking into account that the assumption that a 1 ST = a 2 ST = aST might not be a 377 realistic assumption in a model that described a real life cellular process, a difference in 378 proliferation rates after each vaccination was inserted, assuming a 2 ST was proportional 379 to a 1 ST : a 2 ST = k × a 1 ST . Adding this parameter to the pool of parameters to be Table 8 . Parameter estimates and corresponding 95% confidence intervals (CI) of final model T3a'. ST (0) is assumed to be zero, LT 0 = LT (0) denotes the initial number of LT. The proliferation of ST is constant in time period (0, h 1 ) at rate aST and in time period (2, h 2 ) at rate 0.15.aST . aST is assumed to be group-specific with effects β i (i = 1, 2, 3, 5). Decay of ST happens at rate uST . The number of LT remains constant through time.
393
The same T-cell models were used in the model selection procedure of the 394 gE-specific T-cell data, more details are found in S3 Appendix. The parameter 395 estimations of the final gE-specific T-cell model T1a" are shown in Table 9 . Model T1a" 396 does not differentiate between ST and LT and assumes a constant activation of T-cells 397 in time periods (0, h 1 ) and (2, h 2 ) with a 2 ST = 0.66 × a 1 ST . All parameters were 398 assumed to have random effects with the activation rate being a group-specific 399 parameter. Moreover, individuals 89 and 149 were left out of this dataset since they had 400 too much influence on model convergence.
401 Table 9 . gE-specific T-cell results. Parameter estimates and corresponding 95% confidence intervals (CI) of final model T1a'. No distinction of ST and LT is presumed. T 0 = T (0) denotes the initial number of T-cells. The proliferation of T-cells is constant in time period (0, h 1 ) at rate aT and in time period (2, h 2 ) at rate 0.66.aT . aT is assumed to be group-specific with effects β i (i = 1, 2, 3, 5). Decay of T-cells happens at rate uT .
Vaccine differences 402
Group-specific effects on chosen parameters make it possible to compare each group by 403 examining the differences in these effects. This comparison focuses on different
404
proliferations of B-and T-cells. Group-specific effects were also added on other 405 parameters, more specifically the decay rate and time point h, which marks the end of 406 the proliferation period after vaccination. However, models with these group-specific 407 parameters did either not have an increased AIC compared to a model without this 408 effect, or did not show SAEM convergence.
409
Since a group-specific component was added to the activation of B-/T-cells for each 410 final model, it was subsequently possible to examine whether the HZ/su vaccine caused 411 a higher increase in B-and or T-cells after vaccination, compared to the original OKA 412 vaccine.
413
As a reminder, Table 1 Table 10 . In view of the sample size of groups 1 and 2 (and age), we were 419 mainly interested in β 3 and β 5 . A β i higher than zero indicates a higher activation rate 420 of cells in the groups receiving the HZ/su vaccine, compared to the activation rate in 421 the reference group which received the OKA vaccine. In the case of Varilrix-and 422 gE-specific T-cells, both groups 3 and 5 showed a significant higher activation rate 423 (p < 0.05). The activation rate of gE-specific B-cells also was significantly higher 424 compared to the reference group. Varilrix-specific B-cells also seemed to have a higher 425 proliferation rate, though in the case of groups receiving solely the HZ/su vaccine, not 426 significantly so (p > 0.05). Group-specific parameter estimates, corresponding 95% confidence intervals (CI) and p-values, calculated for Varilrix B-cell, gE B-cell, Varilrix T-cell and gE T-cell data.
Potential associations 428
We started by examining the Varilrix-specific B-cell and T-cell datasets. The datasets increase in T-cells was proportional to an increase in B-cells. We express the expected 432 proportionality factor by m:
Fig 5 
445
We also assessed MIC and Spearman correlations on the same datasets per subgroup, 446 reaching the same conclusion (Table 11) . MIC coefficients, Spearman correlation and corresponding p-values between increase in Varilrix-specific B-cells (B01) and increase in Varilrix-specific T-cells (T 01), calculated for groups 3, 4 and 5. As the sample sizes of groups 1 and 2 were too small (n 1 = 4 and n 2 = 6), those groups were omitted from the analysis.
447
Potential associations between increases in gE-specific T-cells and B-cells were 448 investigated. The scatterplot of T 01 plotted against B 01 is found in Fig S3. 
449
The Spearman correlation of 0.3833 (p = 1.0647e −04 ) suggested there was indeed an 450 association. The MIC score was calculated as 0.4107, which was significant (p < 0.001). 451 In case of a linear relation, the R-square is expected to be close to this MIC score. As 452 the R-square was equal to 0.05593, we could exclude a linear relationship.
453
As before, we also studied the relations between T 01 and B 01 per subgroup (see Table 454 12). The Spearman p-values showed that only in group 3 the Spearman correlation 455 could be considered significant, together with MIC, implying a nonlinear relationship. MIC coefficients, Spearman correlation and corresponding p-values between increase in gE-specific B-cells (B01) and increase in gE-specific T-cells (T 01), calculated for groups 3, 4 and 5. As the sample sizes of groups 1 and 2 were too small (n 1 = 4 and n 2 = 6), those groups were omitted from the analysis.
456
Correlations between the initial number of B-cells B(0), the initial number of T-cells 457 T(0), the number of B-cells at month 1 B(1) and the number of T-cells at month 1 T(1) 458 have also been investigated.
459
We started with the Varilrix-specific B-cell and T-cell data. Again, we only included 460 individuals for whom we had data points B(0), B(1), T(0) and T(1). Spearman those differ greatly depending on the group. However, it has to be noted that group 1 467 and 2 contain a very small number of individuals (4 and 6 individuals respectively). For 468 groups 3 to 5, the results were similar to the results of the correlation between all 469 individuals, and we therefore found no convincing evidence for an association between 470 Varilrix specific B-cells and T-cells. individuals and then split by group. We observed that some correlations seemed to be 477 higher compared to the Varilrix-specific data, however, when examining the Spearman 478 matrices by group, the values between the different groups seemed to vary widely. For 479 this reason, we did not find decisive evidence to include the number of gE-specific 480 T-cells into the B-cell models or vice versa. In this study we used a nonlinear mixed modeling approach using ordinary differential 486 equations to describe B-cell and T-cell dynamics in adults following 2-dose vaccination 487 against VZV by means of the novel subunit VZV gE vaccine (Shingrix, GSK) and 488 live-attenuated VZV (Varilrix, GSK). Our study was motivated by the difficulties in 489 attributing differences between vaccines and vaccination schedules to underlying 490 immunological processes when using "classical" statistical techniques that do not take 491 into account the underlying immunology. Recently, Andraud et al. [4] and Le et al. [5] 492 showed that nonlinear ODE mixed modeling in the setting of vaccinations was capable 493 of giving estimates on several biological parameters.
494
In our study, we assessed Varilrix and VZV gE-specific B-cell and T-cell responses 495 during the 2-dose vaccination schedule for three different schedules (Shingrix only,
496
Varilrix only and the combination of Shingrix and Varilrix on both vaccination 497 moments). We used a standardised inference method to obtain for each setting (immune 498 response and vaccine) the most optimal equation model and parameter estimation 499 (using bootstrapping). Using this robust approach we were able to conclude that the Importantly, this way of modeling allowed us to directly compare several vaccination 511 schedule specific parameters. We found that the Shingrix vaccination schedules led to a 512 more pronounced proliferation of T-cells, however without a difference in T-cell decay 513 rate between vaccination schedules. This shows the benefit of using of mathematical 514 mixed models instead of performing a statistical analysis of the datasets: in the latter 515 case it is possible to prove significant differences between vaccines, however, it is not 516 determinable whether that increase is the result of either a higher proliferation of cells, 517 a lower decay (mainly in the case of a restricted number of data points), or a longer 518 time period (0, h) in which cells are activated.
519
We note that the adjuvant used for the Shingrix vaccine has been reported to be a 520 very potent adjuvant [10] and our modeling approach thus confirms the increased 521 proliferation of T-cells for the Shingrix vaccine.
522
We also assessed whether a correlation existed between the B-cell and T-cell counts, 523 but we did not find a significant association between the two immune response types.
524
This confirms previous findings concerning the glycoprotein-E adjuvant, part of the 525 AS01 B Adjuvant System family, in which it has been shown that this family has been 526 reported to show the lowest correlations between B-cells and T-cells of all families [11] . 527 During our modeling analyses we encountered several limitations. First, we noted 528 that given the limited sample size only models with moderate complexity could be 
